Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study

Simple item page
dc.contributor.authorOruc Z.
dc.contributor.authorKaplan M.A.
dc.contributor.authorGeredeli C.
dc.contributor.authorSari N.Y.
dc.contributor.authorOzaslan E.
dc.contributor.authorAytekin A.
dc.contributor.authorElkiran E.T.
dc.contributor.authorKoca S.
dc.contributor.authorDogan M.
dc.contributor.authorTuran N.
dc.contributor.authorYuce O.
dc.contributor.authorSevinc A.
dc.contributor.authorErcelep O.
dc.contributor.authorIsikdogan A.
dc.date.accessioned2025-04-10T11:06:27Z
dc.date.available2025-04-10T11:06:27Z
dc.date.issued2020
dc.description.abstractPurpose: This study aimed to analyze prognostic factors for survival and the reliability and the effectiveness of eribulin therapy in metastatic breast cancer (MBC) patients. Methods: A total of 80 patients treated with eribulin in 12 medical oncology centers in Turkey between 2013-2017 were retrospectively evaluated. Sixteen potential prognostic variables were assessed for analysis. Results: The patients had received a median of 5 prior chemotherapy regimens and a median of 3 eribulin cycles for MBC. Median progression-free survival (PFS) was 5.5 months (95% Cl: 4.1-7.8) and median overall survival (OS) was 11 months (95 % Cl: 6-15). Multivariate analysis showed that eribulin treatment line was shown to have independent prognostic significance for PFS. PFS difference was demostrated in patients who received 3 chemotherapy lines for advanced disease compared to those who had more than 3 chemotherapy lines [median PFS; 3 lines: 8.6 months (6.2-11) and >3 lines: 4.6 months (3.7-4.6) p=0.00]. The clinical benefit rate (CBR) was 52.5 and 35% in patients treated with three lines and with >3 previous chemotherapeutic regimens. Most common toxicities were neutropenia (62.5%), fatigue (52.5%), alopecia (50%) and nausea (37.5%). Conclusions: Eribulin treatment line was identified as indepedent prognostic factor for PFS in MBC patients. © 2020 Zerbinis Publications. All rights reserved.
dc.identifier.urihttp://hdl.handle.net/20.500.14701/46708
dc.publisherZerbinis Publications
dc.titleIs eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu